Although GLP-1 medications are highly effective for obesity treatment, disregarding sexual health and desire as an essential consideration in initiation of GLP-1 agonist therapy presents a serious concern. This evidence concerns the gene GLP1R and obesity due to melanocortin 4 receptor deficiency.